Innovative peptide-loaded hybrid membrane nanovaccine enables precise personalized immunotherapy for HPV-related cervical diseases
Renjie Wang, Jie Wang, Jinghan Ruan, Chun Gao, Bai Hu, Liang Chen, Bingqing Liao, Ding Ma, Shuguang Tan, Yuanzhen Zhang, Shujie Liao · 2026
Read Innovative peptide-loaded hybrid membrane nanovaccine enables precise personalized immunotherapy for HPV-related cervical diseases by Renjie Wang, Jie Wang, Jinghan Ruan, Chun Gao, Bai Hu, Liang Chen, Bingqing Liao, Ding Ma, Shuguang Tan, Yuanzhen Zhang, Shujie Liao (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13233851.txt.
Description
Renjie Wang and colleagues published a 2026 vaccine study aimed at cervical diseases caused by human papillomavirus. Current treatments often fail to clear the virus fully, and recurrence is common. The team built a tiny-particle vaccine that bundles three parts: skins from tumor cells, skins from bacteria that act as a natural stimulant, and long peptides from three HPV16 proteins.
The particles measured about 177 nanometers and proved stable and safe in tests. Immune guard cells swallowed them readily, matured, and primed strong tumor-specific T cell responses. In mice, the vaccine gathered in lymph nodes, suppressed tumors, and left immune memory that resisted recurrence. Benefits also appeared in human-gene mice and grew stronger alongside chemotherapy and checkpoint immunotherapy, pointing to a flexible platform for personal treatment.
Catalog record
| CREATOR | Renjie Wang, Jie Wang, Jinghan Ruan, Chun Gao, Bai Hu, Liang Chen, Bingqing Liao, Ding Ma, Shuguang Tan, Yuanzhen Zhang, Shujie Liao |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 91 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |